Previous Article | Next Article ![]()
J. Virol., Nov 1995, 6873-6879, Vol 69, No. 11
YL Lu, RP Bennett, JW Wills, R Gorelick and L Ratner
Incorporation of Vpr into human immunodeficiency virus type 1 (HIV-1)
virions is mediated by the Gag protein, independently of other viral
components. We have coexpressed Vpr and Gag constructs in a vaccinia virus
expression system in order to map the region of Gag involved in Vpr
packaging. Deletion of the carboxyl-terminal p6 region of Gag impaired the
ability of Gag to package Vpr. To confirm the role of p6 in Vpr packaging,
Rous sarcoma virus (RSV)-HIV chimeras containing HIV- 1 p6 were
constructed. Although RSV Gag does not package Vpr into virus particles, a
chimera containing HIV-1 p6 is sufficient for Vpr incorporation. To map the
region of p6 involved in Vpr packaging, a series of p6 point mutations and
deletion mutations was analyzed. Mutations in the N-terminal p6
proline-rich domain, for which preliminary evidence shows a marked decrease
in virion incorporated RNA, did not affect Vpr incorporation. Deletion of
residues 1 to 31 of HIV-1 p6 did not affect Vpr packaging, but residues 35
to 47, including an (LXX)4 domain, were required for Vpr incorporation into
virus particles.
Copyright © 1995, American Society for Microbiology
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles
Department of Medicine, Washington University, St. Louis, Missouri 63110, USA.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|